Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quince Therapeutics SEC filings document a rare-disease biotechnology issuer with QNCX common stock registered for trading on the Nasdaq Global Select Market. The filings cover its AIDE drug/device technology, eDSP clinical and regulatory disclosures, operating risks, capital structure and public-company governance.
Recent filings include Form 8-K material-event reports on debt settlement, Nasdaq continued-listing matters, a reverse stock split, board composition and related governance changes. Proxy materials describe director elections, executive compensation, equity awards, board committees and shareholder voting matters, while reporting notices address annual-report timing and required disclosure preparation.
Quince Therapeutics, Inc. reports that its lead asset eDSP failed to meet primary and key secondary endpoints in the pivotal NEAT Phase 3 trial for A‑T, leading the company to discontinue all development of eDSP and other product candidates. With no active pipeline and limited resources, Quince is now primarily focused on preserving cash and exploring strategic alternatives, especially a potential reverse merger, for which it has hired LifeSci Capital as exclusive financial advisor.
The company flags substantial doubt about its ability to continue as a going concern and plans to seek additional equity or debt financing, including potential sales of common stock under an at‑the‑market agreement. Quince also discloses Nasdaq notices for noncompliance with minimum bid price and market value requirements and warns that delisting could occur. As of December 31, 2025, Quince had $17.8 million in cash, cash equivalents and short‑term investments, an accumulated deficit of $460.5 million, and a net loss of $84.0 million for 2025, while continuing to evaluate restructuring options and potential asset sales.
Quince Therapeutics, Inc. is implementing a reverse stock split of its common stock at a 1-for-10 ratio. Every ten shares will be automatically combined into one share, with no change to the $0.001 par value or basic rights of the common stock.
The reverse split becomes effective at 11:59 pm Eastern Time on April 10, 2026, and the shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on April 13, 2026 under the same symbol QNCX but a new CUSIP 22053A206. Immediately after the split, approximately 16,300,795 shares of common stock will be issued and outstanding. Fractional shares will not be issued; affected stockholders will receive cash in lieu of fractional shares.
Quince Therapeutics, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because additional time is needed to complete accounting procedures and disclosures following recent headcount reductions and the negative Phase 3 clinical trial results. The company expects to file within the 15 calendar day extension permitted by Rule 12b-25.
Quince Therapeutics, Inc. has eliminated its loan obligations to the European Investment Bank by paying EUR 4,800,000, or approximately $5.5 million, on March 27, 2026. This payment settled outstanding EIB debt of approximately $16.4 million as of that date, and all obligations under the finance and guarantee agreements were fully satisfied and discharged.
The company describes this settlement as a material milestone that removes a significant debt overhang while it continues a corporate restructuring and an evaluation of strategic alternatives, including potential merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics, Inc. has received two deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Global Select Market. Nasdaq notified the company that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, giving Quince until September 14, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days.
The company also received a notice that its market value of listed securities has been below the required $50,000,000 for 30 consecutive business days, with the same compliance deadline and ten-day cure standard. Quince may seek to transfer to the Nasdaq Capital Market or consider actions such as a reverse stock split, and it can appeal any delisting determination. For now, its stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX.
Group One Trading LLC reports beneficial ownership of 5,942,906 shares of Quince Therapeutics common stock as of 02/28/2026. This holding is reported as 10.67% of the class and is shown with sole voting and dispositive power over those 5,942,906 shares. The filing states the reported total includes options to buy 6,344,500 shares and notes the filer acts as a market maker in Quince options.
Quince Therapeutics filed an 8-K outlining a failed lead drug program, a shift to strategic alternatives, and heightened financial risk. As of December 31, 2025, it preliminarily estimates $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million outstanding under its EIB Loan.
The company’s lead candidate eDSP failed to meet primary and secondary endpoints in the NEAT clinical trial, leaving no current product candidates or meaningful operations. Management has engaged LifeSci Capital to evaluate strategic options, focusing on a potential reverse merger, but notes there are no agreements in place and no assurance of success.
Quince warns that the only opportunity for shareholder return now depends on completing a reverse merger. It highlights risks including potential Nasdaq delisting due to its share price being below $1.00 since January 29, 2026, possible acceleration of the EIB Loan upon a Material Adverse Change, and a scenario where failure to execute a transaction could lead to bankruptcy proceedings in which common stockholders likely receive no value.
Quince Therapeutics, Inc. reported that five members of its Board of Directors — Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray — resigned effective January 30, 2026. The company states these resignations were not due to any disagreement over operations, policies, or practices.
Quince Therapeutics, Inc. filed a current report to note that it has released top-line clinical data from a major late-stage study. On January 29, 2026, the company issued a press release with results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia, a serious inherited disorder. The press release, attached as Exhibit 99.1, contains the detailed trial outcomes and is incorporated by reference into this report.
Quince Therapeutics CEO and CMO Dirk Thye reported a new stock option grant. On January 23, 2026, he was granted an employee stock option to buy 1,000,000 shares of Quince Therapeutics common stock at an exercise price of $3.08 per share.
The filing shows Thye directly holds 1,000,000 derivative securities after this grant. The option vests in 48 equal monthly installments, with 1/48 vesting on the grant date and the remaining portions vesting on the first day of each subsequent month, so the award is scheduled to be fully vested by December 1, 2029.